Ever since his surprise US presidential election win in November, what Donald Trump’s Presidency might mean for pharma has been the subject of plenty of guesswork.
Within minutes of his first press conference as President-elect on Wednesday, Mr Trump gave his clearest indication yet – and pharma stocks reacted according.
Mr Trump called for ‘bidding procedures’ for the drug industry, saying it has a lot of lobbyists and is “getting away with murder.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze